Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business
1. BDX plans to separate Biosciences from Diagnostic Solutions for strategic focus. 2. Post-separation, New BD will aim for $17.8 billion in 2024 revenue. 3. BDX's sales increased 9.8% YoY to $5.17 billion in Q1 2025. 4. The company updated guidance lower, impacting investor sentiment on BDX. 5. Stock price for BDX dropped by 3.88% following Q1 results.